Health Care · Pharmaceutical Preparations · Nasdaq · CIK 1655759 · FYE Dec 31 · Prices AT CLOSE 2026-07-28 (USD) — end-of-day, never a live or intraday quote
Last $8.20Day −0.24%Mkt cap $529M1Y +7.8%Off 52W high −43.5%Vol (1Y) 55.4%
Daily closing price, split-adjusted to the current basis; 3y shown of 1,964 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest6.2% of sh out |
| Days to cover6.6d |
| 13F net flow (QoQ)−2.41% |
| Top-10 13F concentration55.5% |
| Next report (est.)2026-08-10 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Sales (TTM)$89.4M |
| Earnings (TTM)-$221.3M |
| ROE−16.2% |
| Net margin−30.8% |
| ROIC−24.8% |
| Debt / equity0.00× |
| Sales growth 3Y26.0% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD−30.9% |
| 1Y+7.8% |
| 3Y−63.4% |
| 5Y−92.1% |
| Since incept. (ann.)−8.2% |
Total return through 2026-07-28 · series begins 2018-09-27. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)55.4% |
| Ann. volatility (3Y)70.5% |
| Sharpe (1Y)0.41 |
| Sharpe (3Y)−0.08 |
| Max drawdown (1Y)−48.7% |
| Max drawdown (3Y)−88.4% |
| Beta (3Y vs SPY)2.52 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| BlackRock, Inc. | 6.8M | $72M | 10.54% | −7.2% |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 3.9M | $41M | 6.03% | new |
| D. E. Shaw & Co., Inc. | 3.6M | $39M | 5.64% | −1.4% |
| Pfizer Inc | 3.5M | $35M | 5.36% | +0.0% |
| VANGUARD CAPITAL MANAGEMENT LLC | 2.7M | $29M | 4.17% | new |
| TCG Crossover Management, LLC | 2.4M | $25M | 3.70% | −10.5% |
| ARMISTICE CAPITAL, LLC | 2.0M | $21M | 3.07% | +9.9% |
| TWO SIGMA INVESTMENTS, LP | 1.8M | $19M | 2.84% | +84.6% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-11 | −$0.90 | −178.9% | $15.6M | −91.7% |
| 2025-12-31 | 2026-02-24 | — | — | $9.5M | −84.0% |
| 2025-09-30 | 2025-11-05 | −$0.48 | — | $41.9M | −59.1% |
| 2025-06-30 | 2025-08-06 | −$0.84 | — | $22.4M | −70.7% |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-10 is ESTIMATED from filing cadence (median gap 91d) — not company-confirmed.
Reportable 100%
business segments · each slice's share of TAGGED segment revenue in the latest annual filing (XBRL, as filed). Untagged revenue is excluded from the denominator, so slices need not sum to consolidated sales.
